Domain Partners VIII, L.P. 4
4 · BioNano Genomics, Inc · Filed Aug 27, 2018
Insider Transaction Report
Form 4
Domain Partners VIII, L.P.
10% Owner
Transactions
- Conversion
Series C Preferred Stock
2018-08-23−5,426,808→ 0 total→ Common Stock (126,794 underlying) - Conversion
Series B Preferred Stock
2018-08-23−6,810,098→ 0 total→ Common Stock (159,115 underlying) - Conversion
Common Stock
2018-08-23+591,184→ 591,184 total - Conversion
Series D Preferred Stock
2018-08-23−6,396,105→ 0 total→ Common Stock (149,441 underlying) - Conversion
Series D-1 Preferred Stock
2018-08-23−3,682,919→ 0 total→ Common Stock (86,050 underlying) - Purchase
Warrants to Purchase Common Stock
2018-08-23+15,000→ 15,000 totalExercise: $6.13From: 2018-09-20Exp: 2023-09-20→ Common Stock (15,000 underlying) - Conversion
Common Stock
2018-08-23$4.59/sh+337,694$1,550,015→ 929,878 total - Purchase
Common Stock
2018-08-23$6.13/sh+15,000$91,875→ 943,878 total - Conversion
Series B-1 Preferred Stock
2018-08-23−2,986,762→ 0 total→ Common Stock (69,784 underlying) - Conversion
Convertible Promissory Note
2018-08-23→ 0 totalExercise: $4.59→ Common Stock (337,694 underlying)
Footnotes (4)
- [F1]All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date
- [F2]The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- [F3]The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $1,488,952. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share.
- [F4]The Common Stock and Warrants to Purchase Common Stock were issued and sold as units at a purchase price of $6.125 per unit. Each unit consists of one share of Common Stock and one Warrant to purchase one share of Common Stock. The units will separate, and the underlying Common Stock and Warrants will begin trading separately, no later than 30 days following the date of the IPO prospectus, at which time the Warrants will become exercisable for a period of five years.